secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K
Filed at:   2023-04-25T23:59:59+00:00
Accession:  0001104659-23-049365
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio to acquire Spectrum Pharma in all-stock deal with CVRs, 0.1783 exchange ratio
--------------------------------------------------------------------------------

- Each Spectrum share converts into 0.1783 Assertio shares plus one contingent value right (CVR).
- CVRs offer up to $0.20/share total in two milestones: $175M net sales in 2024, $225M in 2025.
- Termination fee of $8.3M payable by either party if deal terminated under certain conditions.
- Merger expected to close by Oct 24, 2023, subject to stockholder approvals and antitrust clearance.
- Spectrum will nominate one board member to Assertio's board effective at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000110465923049365/0001104659-23-049365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000110465923049365/tm2313548d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-049365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer